Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, Alabama, USA.
J Biol Chem. 2022 Jun;298(6):102013. doi: 10.1016/j.jbc.2022.102013. Epub 2022 May 5.
Dysregulation of cyclin-dependent kinases (CDKs) can promote unchecked cell proliferation and cancer progression. Although focal adhesion kinase (FAK) contributes to regulating cell cycle progression, the exact molecular mechanism remains unclear. Here, we found that FAK plays a key role in cell cycle progression potentially through regulation of CDK4/6 protein expression. We show that FAK inhibition increased its nuclear localization and induced G1 arrest in B16F10 melanoma cells. Mechanistically, we demonstrate nuclear FAK associated with CDK4/6 and promoted their ubiquitination and proteasomal degradation through recruitment of CDC homolog 1 (CDH1), an activator and substrate recognition subunit of the anaphase-promoting complex/cyclosome E3 ligase complex. We found the FAK N-terminal FERM domain acts as a scaffold to bring CDK4/6 and CDH1 within close proximity. However, overexpression of nonnuclear-localizing mutant FAK FERM failed to function as a scaffold for CDK4/6 and CDH1. Furthermore, shRNA knockdown of CDH1 increased CDK4/6 protein expression and blocked FAK inhibitor-induced reduction of CDK4/6 in B16F10 cells. In vivo, we show that pharmacological FAK inhibition reduced B16F10 tumor size, correlating with increased FAK nuclear localization and decreased CDK4/6 expression compared with vehicle controls. In patient-matched healthy skin and melanoma biopsies, we found FAK was mostly inactive and nuclear localized in healthy skin, whereas melanoma lesions showed increased active cytoplasmic FAK and elevated CDK4 expression. Taken together, our data demonstrate that FAK inhibition blocks tumor proliferation by inducing G1 arrest, in part through decreased CDK4/6 protein stability by nuclear FAK.
细胞周期蛋白依赖性激酶(CDKs)的失调可促进不受控制的细胞增殖和癌症进展。尽管粘着斑激酶(FAK)有助于调节细胞周期进程,但确切的分子机制尚不清楚。在这里,我们发现 FAK 通过调节 CDK4/6 蛋白表达在细胞周期进程中发挥关键作用。我们表明,FAK 抑制增加了其核定位并诱导 B16F10 黑色素瘤细胞中的 G1 期阻滞。在机制上,我们证明核 FAK 与 CDK4/6 相关,并通过募集细胞分裂周期蛋白 1(CDH1)促进它们的泛素化和蛋白酶体降解,CDH1 是后期促进复合物/细胞周期蛋白 E3 连接酶复合物的激活剂和底物识别亚基。我们发现 FAK N 端 FERM 结构域充当支架,使 CDK4/6 和 CDH1 紧密接近。然而,过表达非核定位的突变体 FAK FERM 不能作为 CDK4/6 和 CDH1 的支架发挥作用。此外,CDH1 的 shRNA 敲低增加了 CDK4/6 蛋白表达,并阻止了 FAK 抑制剂诱导的 B16F10 细胞中 CDK4/6 的减少。在体内,我们表明,与载体对照相比,药理 FAK 抑制可降低 B16F10 肿瘤大小,这与 FAK 的核定位增加和 CDK4/6 表达降低相关。在患者匹配的健康皮肤和黑色素瘤活检中,我们发现 FAK 在健康皮肤中主要是无活性和核定位的,而黑色素瘤病变显示出增加的活性细胞质 FAK 和 CDK4 表达升高。总之,我们的数据表明,FAK 抑制通过诱导 G1 期阻滞来阻止肿瘤增殖,部分原因是核 FAK 降低 CDK4/6 蛋白稳定性。